ClinicalTrials.gg
CompletedNCT01567085Updated May 3, 2019Results posted

Safety & Efficacy Of Eculizumab In The Prevention Of AMR In Sensitized Recipients Of A Kidney Transplant From A Deceased Donor

A Phase 2 interventional study of Eculizumab in Stage V Chronic Kidney Disease, sponsored by Alexion Pharmaceuticals, Inc.. Completed at 15 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-05-03.

Sponsored by Alexion Pharmaceuticals, Inc. (part of AstraZeneca) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
80
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

Primary Objective:

To evaluate the safety and potential efficacy of eculizumab to prevent AMR in sensitized recipients of deceased donor kidney transplants.

02

Conditions studied

  • Stage V Chronic Kidney Disease
03

In context

Lead sponsor

Alexion Pharmaceuticals, Inc. is the lead sponsor of 255 studies on the registry; 23 are open to participants now.

Of its 101 completed or terminated interventional studies of FDA-regulated products, 75 (74%) have results posted.

First submitted before Alexion Pharmaceuticals, Inc. became part of AstraZeneca.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female participants ≥18 years old.
  2. Participants with Stage V chronic kidney disease who received a kidney transplant from a deceased donor to whom they were sensitized.
  3. History of prior exposure to HLA (human leukocyte antigen):

    • Prior solid organ or tissue allograft
    • Pregnancy
    • Blood transfusion
    • Prior exposure to specific donor's HLA

Exclusion criteria

Exclusion Criteria:

  1. Has received treatment with eculizumab at any time prior to enrolling in this study.
  2. Blood type (A, B, and O blood glycoproteins-blood type) incompatible with deceased donor.
  3. History of severe cardiac disease.
  4. Prior splenectomy.
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
80 participants (actual)

Study arms

  • Experimental
    Eculizumab

    Eculizumab 1200 milligrams (mg) was administered intravenously (IV) over 25 to 45 minutes 1 hour prior to kidney allograft reperfusion. Eculizumab 900 mg was administered IV over 25 to 45 minutes on post-transplantation Days 1 and 7, and on post-transplantation Days 14, 21, and 28, plus or minus 2 days. Eculizumab 1200 mg was administered IV over 25 to 45 minutes on post-transplantation Days 35, 49, and 63, plus or minus 2 days.

    Drug: Eculizumab

Interventions

06

What researchers measure

Primary outcomes

  1. Post-transplantation Treatment Failure In The First 9 Weeks Post Transplantation

    Results are reported for post-transplantation treatment failure and composite endpoints, defined as the occurrence of biopsy-proven acute antibody-mediated rejection (AMR), graft loss, death, or loss to follow-up (including discontinuation) in the first 9 weeks post transplantation. The diagnosis of acute AMR (occurring within the first 9 weeks post transplantation) was based on kidney allograft dysfunction and a biopsy performed due to suspected rejection, proteinuria, increased serum creatinine, or acute tubular necrosis. Treatment failure was the occurrence of at least 1 of the composite endpoint components by Week 9 post transplantation. A participant experiencing multiple events was only counted once for the composite endpoint.

    Time frame: Baseline, Week 9

Other outcomes

  1. Cumulative Incidence Function (CIF) Of Other Adverse Events (AEs) Of Interest At Month 12

    Specific analyses of other AEs of interest that occurred at Month 12 included cumulative incidence of clinically significant infection (CSI); post-transplant lymphoproliferative disease (PTLD); malignancies; biopsy-proven acute cellular rejection (ACR) of any grade meeting Banff 2007 criteria; allograft loss for reasons other than AMR. CSIs were defined as infections (confirmed by culture, biopsy, genomic, or serologic findings) that required hospitalization or anti-infective treatment, or otherwise deemed significant by the Investigator. CSI subcategories of interest included cytomegalovirus (CMV) disease; BK virus disease; encapsulated bacterial infection; fungal infections; aspergillus infections. Results are reported as CIF, where a larger CIF indicates a higher incidence of an AE, and were calculated using Statistical Analysis System software and macro CIF. A summary of serious and all other non-serious AEs regardless of causality is located in the Reported Adverse Events module.

    Time frame: Baseline, Month 12

  2. Participants That Developed Severe ACR (Other AE Of Interest) At Month 12

    This outcome measure focuses on the other AE of interest, severe ACR, which occurred at Month 12. It pertains specifically to the number of participants who developed severe ACR that did not respond to thymoglobulin or other lymphocyte-depleting agents. A summary of serious and all other non-serious AEs, regardless of causality, is located in the Reported Adverse Events module.

    Time frame: Baseline, Month 12

07

Results

Posted May 3, 2019

Participant flow

Participant flow — Overall Study
MilestoneEculizumab
Started80
Received at least 1 dose of study drug80
Completed60
Not completed20
Withdrew: Death6
Withdrew: Adverse event6
Withdrew: Lost to follow-up3
Withdrew: Graft loss2
Withdrew: Renal transplantectomy1
Withdrew: Returned to chronic dialysis1
Withdrew: Terminal chronic kidney dysfunction1

Outcome measures

PrimaryPost-transplantation Treatment Failure In The First 9 Weeks Post Transplantation

Results are reported for post-transplantation treatment failure and composite endpoints, defined as the occurrence of biopsy-proven acute antibody-mediated rejection (AMR), graft loss, death, or loss to follow-up (including discontinuation) in the first 9 weeks post transplantation. The diagnosis of acute AMR (occurring within the first 9 weeks post transplantation) was based on kidney allograft dysfunction and a biopsy performed due to suspected rejection, proteinuria, increased serum creatinine, or acute tubular necrosis. Treatment failure was the occurrence of at least 1 of the composite endpoint components by Week 9 post transplantation. A participant experiencing multiple events was only counted once for the composite endpoint.

Time frame:
Baseline, Week 9
Reported as:
Count of participants · Participants
Post-transplantation Treatment Failure In The First 9 Weeks Post Transplantation
ParticipantsEculizumab
Treatment Failure - Yes7
Treatment Failure - No73
Biopsy-proven Acute AMR3
Graft Loss4
Death1
Lost to Follow-up (Including Discontinuation)1
Statistical analysis
  • Eculizumab · Exact binomial test · p = < 0.001 (The p-value was calculated from an exact binomial test, where the null hypothesis was that the true failure rate = 40%.)Exact 95% confidence interval (3.6, 17.2)
Other pre-specifiedCumulative Incidence Function (CIF) Of Other Adverse Events (AEs) Of Interest At Month 12

Specific analyses of other AEs of interest that occurred at Month 12 included cumulative incidence of clinically significant infection (CSI); post-transplant lymphoproliferative disease (PTLD); malignancies; biopsy-proven acute cellular rejection (ACR) of any grade meeting Banff 2007 criteria; allograft loss for reasons other than AMR. CSIs were defined as infections (confirmed by culture, biopsy, genomic, or serologic findings) that required hospitalization or anti-infective treatment, or otherwise deemed significant by the Investigator. CSI subcategories of interest included cytomegalovirus (CMV) disease; BK virus disease; encapsulated bacterial infection; fungal infections; aspergillus infections. Results are reported as CIF, where a larger CIF indicates a higher incidence of an AE, and were calculated using Statistical Analysis System software and macro CIF. A summary of serious and all other non-serious AEs regardless of causality is located in the Reported Adverse Events module.

Time frame:
Baseline, Month 12
Reported as:
Number · Proportion of Adverse Events
Cumulative Incidence Function (CIF) Of Other Adverse Events (AEs) Of Interest At Month 12
Proportion of Adverse EventsEculizumab
Confirmed CSI0.7989 (0.69 to 0.87)
CMV Infection0.2994 (0.20 to 0.40)
BK Virus Infection0.1536 (0.08 to 0.24)
Encapsulated Bacterial Infection0.1642 (0.09 to 0.25)
Fungal Infection0.1287 (0.07 to 0.21)
Aspergillus Infection0 (0 to 0)
PTLD0.0264 (0.00 to 0.08)
Malignancies0.0264 (0.00 to 0.08)
Biopsy-proven ACR0.0375 (0.01 to 0.10)
Allograft Loss For Reasons Other Than AMR0.1132 (0.06 to 0.19)
Other pre-specifiedParticipants That Developed Severe ACR (Other AE Of Interest) At Month 12

This outcome measure focuses on the other AE of interest, severe ACR, which occurred at Month 12. It pertains specifically to the number of participants who developed severe ACR that did not respond to thymoglobulin or other lymphocyte-depleting agents. A summary of serious and all other non-serious AEs, regardless of causality, is located in the Reported Adverse Events module.

Time frame:
Baseline, Month 12
Reported as:
Count of participants · Participants
Participants That Developed Severe ACR (Other AE Of Interest) At Month 12
ParticipantsEculizumab
Participants That Developed Severe ACR (Other AE Of Interest) At Month 123

Adverse events

Collected over Adverse event data were collected beginning on the day of transplantation, Day 0, through 12 months post transplantation.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Eculizumab6/80 (7.5%)70/80 (87.5%)80/80 (100%)
Most frequent serious events
Showing 10 of 150
Most frequent serious events
EventEculizumab
Kidney transplant rejectionImmune system disorders25/80
Acute kidney injuryRenal and urinary disorders12/80
Delayed graft functionInjury, poisoning and procedural complications10/80
PyelonephritisInfections and infestations7/80
Blood creatinine increasedInvestigations6/80
Bacterial pyelonephritisInfections and infestations5/80
Cytomegalovirus infectionInfections and infestations5/80
PneumoniaInfections and infestations5/80
HaematuriaRenal and urinary disorders5/80
Acute pulmonary oedemaRespiratory, thoracic and mediastinal disorders5/80
Most frequent other events
Showing 10 of 120
Most frequent other events
EventEculizumab
AnaemiaBlood and lymphatic system disorders51/80
DiarrhoeaGastrointestinal disorders37/80
Urinary tract infectionInfections and infestations32/80
Oedema peripheralGeneral disorders31/80
HypertensionVascular disorders31/80
LeukopeniaBlood and lymphatic system disorders30/80
NauseaGastrointestinal disorders25/80
HyperkalaemiaMetabolism and nutrition disorders23/80
Kidney transplant rejectionImmune system disorders22/80
HeadacheNervous system disorders22/80

Baseline characteristics

Safety Population: enrolled participants who received at least 1 dose of eculizumab.

Age, Continuous
Age, Continuous(years)Eculizumab
Mean50.7 ± 11.26
Sex: Female, Male
Sex: Female, Male(Participants)Eculizumab
Female48
Male32
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Eculizumab
American Indian or Alaska Native0
Asian5
Native Hawaiian or Other Pacific Islander0
Black or African American7
White59
Unknown or Not Reported9
08

Study locations

15 sites
  • Adelaide, 5000, Australia
  • Camperdown, 2050, Australia
  • Parkville, 3050, Australia
  • Bordeaux, 33076, France
  • Paris, 75010, France
  • Paris, 75743, France
  • Toulouse, 31059, France
  • Tours, 37044, France
  • Brescia, 25123, Italy
  • Padova, 35128, Italy
  • Barcelona, 08907, Spain
  • Gothenburg, 413 45, Sweden
  • Uppsala, 751 85, Sweden
  • Cambridge, CB2 2QQ, United Kingdom
  • London, SE1 9RT, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2012 to primary completion in Jun 2015, 33 months.

Results were first posted in May 2019, 3 years 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 27, 2012
First posted
Mar 30, 2012
StartActual
Aug 29, 2012
Primary completionActual
Jun 11, 2015
CompletionActual
May 24, 2017
Results first posted
May 3, 2019
Last update
May 3, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 3, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01567085
Responsible party
Sponsor
First posted
Mar 30, 2012
Start date
Aug 29, 2012
Primary completion
Jun 11, 2015
Completion
May 24, 2017
Results posted
May 3, 2019
Last update
May 3, 2019

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Eculizumab

Start the discussion